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Background
Allergy diagnosis is based on the history, clinical symp-
toms and physical examination of the patient in combi-
nation with results of in vivo and in vitro test. Today the
allergy diagnosis can be refined using molecular allergol-
ogy, which allows the quantification of allergen specific
IgE antibodies to a single, pure allergen molecule (com-
ponent). This contributes to a more exact diagnosis, and
thereby enables a more accurate disease prognosis in
terms of tolerance development or risk assessment lead-
ing to an improved patient management. Depending on
how unique the components are in distribution and
structure, they are classified as Specific or Cross-reactive.
Specific allergen components are more or less unique for
their source, and are found only in a rather limited num-
ber of very closely related species. In each allergen
sources there are one or more specific allergen compo-
nents and sensitization to these indicate a true/genuine
sensitization, meaning that the corresponding allergen
source is the primary cause of the clinical symptoms.
Cross reactive allergens on the other hand, are widely
distributed (also in distantly related species) and due to
their high degree of structural similarity may cause IgE
antibody cross-reactivity. Components can be either
labile or stable depending on their structure. Stable pro-
teins are not easily broken down by cooking, processing
or by enzymes in the saliva and in the gut. Stable proteins
will reach the circulation in a more or less intact form
and therefore potentially give rise to systemic reactions.
Labile proteins that are easily broken down by proces-
sing, cooking or by enzymes in the saliva or gut will
mainly give rise to local reactions, such as Oral Allergy
Syndrome.
Conclusions
The Molecular Allergology allows: 1) To identify the
right patients for Specific Immunotherapy: sensitization
to specific allergen components is essential for successful
Specific Immunotherapy. By matching patients having a
genuine sensitization with an extract from the relevant
source, treatment outcome is improved. 2) To explain
symptoms due to cross-reactivity: symptoms elicited by
cross-reacting antibodies can be distinguished from those
caused by genuine sensitization which is important for
patient management and for giving adequate avoidance
advice. In cases where only cross-reactive sensitization is
identified, further testing to find the primary sensitizer
should be undertaken. 3) To assess the clinical risk for
reaction: sensitization to allergen components that are
stable may elicit systemic reactions, as well as local reac-
tions, while sensitization to labile components is con-
nected mainly with local reactions.
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